The benefits of HIPEC include improved local control of cancer, reduced recurrence rates, and enhanced survival outcomes for ...

Real-world safety of trastuzumab deruxtecan with gastric cancer: All-patient post-marketing surveillance study in Japan. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Researchers have achieved recent therapeutic advancements for peritoneal cancer treatment through surgical procedures combined with chemotherapy access to emerging therapeutic options. Additionally, ...

The PRIs represents novel promising feature of predicting peritoneal recurrence of GC and sheds light on the improvement of the personalized management of GC patients after surgery. With the goal of ...

Adding intraperitoneal paclitaxel to intravenous paclitaxel and oral S-1 improved survival in patients with gastric cancer and peritoneal metastasis.

Patients suffering from PC or liver metastasis caused by cancer of the appendix, colon, rectosigmoid or rectum as primary tumor sites were included. For immunohistochemistry, FFPE samples of patients ...

Nesuparib is under clinical development by Onconic Therapeutics and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase ...

Prognostic factors for gastric cancer patients with positive peritoneal cytology who underwent upfront surgery. Short- and long-term outcomes of conversion surgery for initially unresectable advanced ...

A three-day conference on Peritoneal Surface malignancy was held at Thangam Hospital and Cancer Center, Namakkal. Peritoneal Surface malignancy (PSM) is a super special branch dealing with cancers of ...